Compare Lockheed Martin Corporation (LMT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Sanofi SA — how do they compare? Lockheed Martin Corporation trades at $606.82 (market cap $137.96B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Lockheed Martin Corporation is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| LMT | SNY | |
|---|---|---|
Market Cap | $137.96B | $104.30B |
Sector | Industrials | Health |
52-Week High | $676.70 | $52.34 |
52-Week Low | $431.56 | $41.33 |
Enterprise Value | $154.71B | $124.19B |
Dividend Yield | 2.31% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $606.71, up 0.59% on the day, near its consensus price target of $608. The stock shows bullish technical momentum with strong moving average signals and is supported by a record $230.4 billion backlog as of Q2 2026 (Seeking Alpha, August 4, 2026). Recent earnings beat expectations in Q2 2026 with EPS of $7.94 versus $7.22 estimated, though Q4 2025 and Q1 2026 results missed. The company maintains robust cash flow, with 2025 operating cash flow at $8.56 billion, and benefits from major defense contracts, including a $53.9 billion Patriot missile order (The Motley Fool, August 11, 2026).
Outlook is positive due to strong defense spending trends and execution, but risks include earnings volatility and debt levels. The stock offers steady dividends and growth potential, with analyst consensus leaning bullish. Key risks involve reliance on government contracts and macroeconomic pressures on defense budgets.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
